GGrantIndex
← Leaderboards

Michael W Cho

Case Western Reserve University

Google Scholar ↗PubMed ↗ORCID ↗
$12,621,911
Attributed
$12,924,317
Total exposure
18
Grants
14
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $4.8M · FY2005–23
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$22,980,944 · 20

By mechanism

U19$8,402,130 · 4
P01$8,357,251 · 3
R21$4,448,801 · 10
R33$1,167,950 · 1
R43$597,312 · 1
R13$7,500 · 1

Top collaborators

Most similar at Case Western Reserve University

Same institution · by research overlap

Others in their field

Top investigators on “Hiv-1”

Research focus

Hiv-1Novel VaccinesAntigensAids VaccinesImmunogenicVaccinesVaccine DevelopmentNeutralizing AntibodyBasePropertyVirusMembraneImmune ResponseProteinsEpitopesAntibodiesDesignVariantAids Vaccine DevelopmentInfectionResearch PersonnelInnovationResponseImmunogenicity

Grant awards (56)

Induction of bnAbs against HIV-1 gp41.$300,000
R43 · FY2023 · MH
Induction of bnAbs against HIV-1 gp41.$297,312
R43 · FY2022 · MH
Evaluation of a Novel Antigen-Enhanced, Anti-Idiotypic Antibody Vaccine Strategy$250,449
R21 · FY2020 · AI · contact PI
Induction of broadly neutralizing antibodies against CD4 binding site$226,811
R21 · FY2019 · AI · contact PI
Development of novel immunogens to induce 10E8-like neutralizing antibodies$226,811
R21 · FY2019 · AI · contact PI
Evaluation of a Novel Antigen-Enhanced, Anti-Idiotypic Antibody Vaccine Strategy$204,113
R21 · FY2019 · AI · contact PI
Induction of broadly neutralizing antibodies against CD4 binding site$188,570
R21 · FY2018 · AI · contact PI
Development of novel immunogens to induce 10E8-like neutralizing antibodies$188,469
R21 · FY2018 · AI · contact PI
Development of a vaccine strategy using antibody-complexed antigens$182,729
R21 · FY2017 · AI · contact PI
Development of a vaccine strategy using antibody-complexed antigens$220,422
R21 · FY2016 · AI · contact PI
Vaccines Against Antigenically Variable Viruses Symposium$7,500
R13 · FY2016 · AI · contact PI
Enhancing B cell immunity against HIV-1 using novel vaccine delivery platforms$1,281,293
U19 · FY2013 · AI · contact PI
Vaccine Delivery Platform Development$462,357
U19 · FY2013 · AI · contact PI
Protein Production Core$165,619
U19 · FY2013 · AI · contact PI
Administrative Core$132,448
U19 · FY2013 · AI · contact PI
Enhancing B cell immunity against HIV-1 using novel vaccine delivery platforms$1,245,610
U19 · FY2012 · AI · contact PI
Characterization of immunogenic and structural properties of HIV-1 envelope$951,914
P01 · FY2012 · AI · contact PI
Antigen Design, Production and Vaccine Development$674,945
P01 · FY2012 · AI · contact PI
Vaccine Delivery Platform Development$659,584
U19 · FY2012 · AI · contact PI
Targeting gp41 to elicit neutralizing antibodies against HIV-1$384,944
R33 · FY2012 · AI · contact PI
Protein Production Core$142,074
U19 · FY2012 · AI · contact PI
Administrative Core$98,752
U19 · FY2012 · AI · contact PI
Administrative Core$34,390
P01 · FY2012 · AI · contact PI
Characterization of immunogenic and structural properties of HIV-1 envelope$1,455,810
P01 · FY2011 · AI · contact PI
Enhancing B cell immunity against HIV-1 using novel vaccine delivery platforms$1,246,317
U19 · FY2011 · AI · contact PI
Antigen Design, Production and Vaccine Development$768,541
P01 · FY2011 · AI · contact PI
Vaccine Delivery Platform Development$491,520
U19 · FY2011 · AI · contact PI
Targeting gp41 to elicit neutralizing antibodies against HIV-1$387,966
R33 · FY2011 · AI · contact PI
Protein Production Core$171,883
U19 · FY2011 · AI · contact PI
Administrative Core$141,200
U19 · FY2011 · AI · contact PI
Administrative Core$130,506
P01 · FY2011 · AI · contact PI
Enhancing B cell immunity against HIV-1 using novel vaccine delivery platforms$1,310,664
U19 · FY2010 · AI · contact PI
Characterization of immunogenic and structural properties of HIV-1 envelope$962,051
P01 · FY2010 · AI · contact PI
Vaccine Delivery Platform Development$518,775
U19 · FY2010 · AI · contact PI
Antigen Design, Production and Vaccine Development$503,199
P01 · FY2010 · AI · contact PI
Targeting gp41 to elicit neutralizing antibodies against HIV-1$395,040
R33 · FY2010 · AI · contact PI
Protein Production Core$182,310
U19 · FY2010 · AI · contact PI
Administrative Core$151,724
U19 · FY2010 · AI · contact PI
Administrative Core$92,101
P01 · FY2010 · AI · contact PI
Antigen Design, Production and Vaccine Development$573,777
P01 · FY2009 · AI · contact PI
Characterization of immunogenic and structural properties of HIV-1 envelope$427,354
P01 · FY2009 · AI · contact PI
Targeting gp41 to elicit neutralizing antibodies against HIV-1$196,839
R21 · FY2009 · AI · contact PI
Targeting gp41 to elicit neutralizing antibodies against HIV-1$3,166
R21 · FY2009 · AI · contact PI
Characterization of immunogenic and structural properties of HIV-1 envelope$1,175,614
P01 · FY2008 · AI · contact PI
Antigen Design, Production and Vaccine Development$607,049
P01 · FY2008 · AI · contact PI
Targeting gp41 to elicit neutralizing antibodies against HIV-1$202,222
R21 · FY2008 · AI · contact PI
HIV-1 vaccine using variable loop-modified envelopes$224,107
R21 · FY2006 · AI · contact PI
A novel approach of generating combinatorial libraries$169,728
R21 · FY2006 · GM · contact PI
Development of a vaccine against SARS-CoV$306,000
R21 · FY2005 · AI
HIV-1 vaccine using variable loop-modified envelopes$229,500
R21 · FY2005 · AI
A novel approach of generating combinatorial libraries$208,575
R21 · FY2005 · GM
Development of a vaccine against SARS-CoV$302,290
R21 · FY2004 · AI
Developing HIV-1 Vaccine Using Parainfluenza Virus$229,500
R21 · FY2004 · AI
Developing HIV-1 Vaccine Using Parainfluenza Virus$229,500
R21 · FY2003 · AI
Development of a Safer Smallpox Vaccine$229,500
R21 · FY2003 · AI
Development of a Safer Smallpox Vaccine$229,500
R21 · FY2002 · AI